Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Filter News
Show All Results
News By Country
News By Tag
Gene Therapy Remove


August 2014
Th We Tu Mo Su Sa Fr
21 20 19 18 17 16 15

gene therapy Press Releases

  + XML/RSS  



By Mary Ann Liebert, Inc., publishers
Contact: Kathryn Ruehle, Mary Ann Liebert, Inc, (914) 740-2100, kruehle@liebertpub.com Splice-Switching Oligonucleotide Therapeutics Is Promising New Method for Editing Gene Transcripts New Rochelle, NY—In splice-switching, an innovative therapeutic...

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com Frederic Bushman, PhD Receives Pioneer Award for Advancing Therapeutic Gene Delivery Methods New Rochelle, NY—Frederic D.

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com James Wilson, MD, PhD Receives Pioneer Award for Research on Gene Therapy and AAV Gene Delivery Systems New Rochelle, NY—James M.

By Mary Ann Liebert, Inc., publishers
Marina Cavazzana, MD, PhD, Paris Descartes University, and Adrian J. Thrasher, MD, PhD, University College London Institute of Child Health, have been honored with the Pioneer Award for basic and clinical gene therapy for immunodeficiency disorders.

By Mary Ann Liebert, Inc., publishers
for Developing First In Vivo Adenoviral Gene Delivery Vector

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.

All Press Releases

By Mary Ann Liebert, Inc., publishers
Contact: Kathryn Ruehle, Mary Ann Liebert, Inc, (914) 740-2100, kruehle@liebertpub.com Splice-Switching Oligonucleotide Therapeutics Is Promising New Method for Editing Gene Transcripts New Rochelle, NY—In splice-switching, an innovative therapeutic...

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com Frederic Bushman, PhD Receives Pioneer Award for Advancing Therapeutic Gene Delivery Methods New Rochelle, NY—Frederic D.

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com James Wilson, MD, PhD Receives Pioneer Award for Research on Gene Therapy and AAV Gene Delivery Systems New Rochelle, NY—James M.

By Mary Ann Liebert, Inc., publishers
Marina Cavazzana, MD, PhD, Paris Descartes University, and Adrian J. Thrasher, MD, PhD, University College London Institute of Child Health, have been honored with the Pioneer Award for basic and clinical gene therapy for immunodeficiency disorders.

By Mary Ann Liebert, Inc., publishers
Contact: Jennifer Quigley, Mary Ann Liebert, Inc, (914) 740-2100, ext.

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100 (914) 740-2100, ext. 2156, vcohn@liebertpub.com Joseph Glorioso, PhD Receives Pioneer Award for Engineering Herpes Simplex Virus Gene Delivery Systems New Rochelle, NY—Joseph C.

By Mary Ann Liebert, Inc., publishers
for Developing First In Vivo Adenoviral Gene Delivery Vector

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.

By AveXis
Dallas, TX- AveXis-BioLife is pleased to announce the launch of the company’s brand new website: www.avexisinc.com.

By Mary Ann Liebert, Inc., publishers
The scientists who led the team that developed Glybera, the first gene therapy drug approved for use in the Western world, provide a fascinating first-person account of their pioneering work in Human Gene Therapy.

By Mary Ann Liebert, Inc., publishers
New Rochelle, NY, March 14, 2013—Severe chronic pain associated with conditions such as bladder pain syndrome/interstitial cystitis often require the use of opioid medication, with the risk of dependency and serious adverse reactions.

By Mary Ann Liebert, Inc., publishers
Follow-up results from one of several groundbreaking gene therapy studies reported in 2008 in patients with an inherited form of retinal blindness confirmed the earlier positive results of substantial improvement in vision.

By NTSAD
First human trial for Tay-Sachs, Canavan and other rare enzyme deficiency diseases plans to begin in early 2013 thanks to NTSAD, the nation's oldest patient advocacy organization, which leads efforts to find a cure or treatment.

By www.creativebiomart.net
After years of development and repeated rejections, uniQure finally got permission to market its gene therapy—Glybera.

By Mary Ann Liebert, Inc., publishers
The inaugural issue of BioResearch Open Access, a new bimonthly peer-reviewed open access journal, was released today by Mary Ann Liebert, Inc., publishers.

By Orion PR & Digital Pvt Ltd
Dr Agarwal’s Hospitals, announces a new technique in the world of Ophthalmology, done for the first time ever in the world “Autologous Retinal Transplant”.

By Mary Ann Liebert, Inc., publishers
BioResearch Open Access, a new bimonthly peer-reviewed open access journal, will launch in March 2012 by Mary Ann Liebert, Inc., publishers (www.liebertpub.com).

By Mary Ann Liebert, Inc., publishers
The time for commercial development of gene therapy has come. Patients with diseases treatable and curable with gene therapy deserve access to the technology.

By Genevolve Vision Diagnostics, Inc.
The genetic test will be available to eye doctors by the end of 2011. Applying gene therapy to humans in a FDA monitored clinical trial is planned.

By Alain Lafeuillade
The future of fighting the AIDS epidemic and possibly leading to HIV eradication rests on two new approaches. Drugs that activate the latent cells and gene therapy are the two new possible strategies in the future fight against the disease.

By Shushmul Maheshwari
The rising number of research & development work around the world will boost the global Gene Therapy market to new heights, says RNCOS in its latest research.

By Alain Lafeuillade
Scientific advances towards an HIV cure will be the main topic of the second day of the "International Symposium on HIV & Emerging Infectious Diseases".

By Mary Ann Liebert, Inc., publishers
Disorders of the eye are excellent targets for gene therapy because the ocular environment is readily accessible, relatively easy to monitor, and sequestered from the rest of the body

By Gene Therapy Net
Results of Poll on Gene Therapy Net. More than 60% of the people are of the opinion that gene therapy will be a vital part of future health care.

By Mary Ann Liebert Inc., publishers
Give caffeine to cells engineered to produce viruses used for gene therapy and the cells can generate 3- to 8-times more virus, according to a paper published in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc.

By Mary Ann Liebert, Inc., publishers
A new, simplified method for producing large amounts of viral vector cassettes capable of shuttling genes into host cells will help advance the promising field of gene therapy as applications move into large animal studies and human clinical trials.

By Mary Ann Liebert, Inc., publishers
The introduction of a new, fully characterized viral vector for use as reference material to help standardize gene therapy protocols in research applications and human clinical trials is described in an article in Human Gene Therapy

By Synpromics Ltd
Synpromics announces its incorporation as Scotland’s latest biotech company. The new company aims to focus its activities in the area of synthetic biology and has acquired its patents from its managing director; Dr Michael Roberts.

By Fight SMA
Richmond-based FightSMA announced today a new fundraising campaign for spinal muscular atrophy gene therapy, “Realizing the Dream.”

By J.Roberts
Up-to-date on-stop information on gene therapy with 72 tables and 13 figures

By American Society of Gene & Cell Therapy
Molecular Therapy, the journal of the American Society of Gene & Cell Therapy, has its research cited up to twice as often as other journals in the field, according to new Thompson Reuters reports.

By Louisiana Gene Therapy Research Consortium
The Louisiana Gene Therapy Research Consortium celebrates 10 years of providing new hope for people with serious inherited and acquired diseases by helping Louisiana scientists discover successful cell and gene therapies.

By Gene Therapy Review
The Gene Therapy Review announces both the release of its first print edition, featuring all the educational articles submitted to the genetherapyreview.com website, and its partnership with EBSCO publishing.

By The American Society of Gene & Cell Therapy
The American Society of Gene & Cell Therapy (ASGCT) Board of Directors recently unveiled a new mission statement and goals for ASGCT, as well as a new logo and website domain for the Society.

By Gene Therapy Net
Gene Therapy Net is pleased to announce the launch of a gene therapy quiz in combination with an in depth review of the concept behind gene therapy in order to boost awareness.

By American Society of Gene Therapy
Stem cells containing protective genes may provide permanent control of human immunodeficiency virus (HIV) in infected individuals, according to research presented at the American Society of Gene Therapy 12th Annual Meeting, May 30.

By American Society of Gene Therapy
Gene therapy should be used in tandem with stem cell therapy to enhance the reliability and efficacy of stem cells, according to research presented at the American Society of Gene Therapy’s 12th Annual Meeting, May 30.

By American Society of Gene Therapy
A herpes virus better known for causing cold sores has shown promise as a treatment for late-stage skin cancer, according to research presented at the American Society of Gene Therapy’s 12th Annual Meeting, May 27.

By American Society of Gene Therapy
In the past 20 years, gene therapy has advanced from concept to effective clinical application, according to a presentation at the American Society of Gene Therapy’s 12th Annual Meeting, May 27.

By GenScript Corp.
GenScript offers low-endotoxin plasmids in a selection of quantities.

By Gene Therapy Net
Researchers experience that it is hard to keep up with new gene therapy developments. With the launch of a new online portal this year, relevant gene therapy information is now collected on a comprehensive website.

By Mary Ann Liebert, Inc., publishers
Gene therapy to replace the faulty CLN2 gene, which causes a neurodegenerative disease that is fatal by age 8-12 years, was able to slow significantly the rate of neurologic decline in treated children.

By Thieme Publishing Group
Neuro-Oncology: The Essentials successfully delivers the essence of neuro-oncology in an attractive, user-friendly format. The new edition is an invaluable reference tool for neurosurgeons, neurologists, oncologists, residents as well as students.

By Mary Ann Liebert, Inc., publishers
RNAi represents an innovative new strategy for using small RNA molecules to silence specific genes associated with disease processes, and a series of review articles describing applications of RNAi and microRNAs will begin in Human Gene Therapy.

By Mary Ann Liebert, Inc., publishers
Can a patient who agrees to participate in a study of a gene therapy protocol give informed consent and understand the risks when the consent forms are highly technical and the physician or institution seeking their consent has a stake in the study?



Page:
  • 1

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share